Clovis Oncology (NASDAQ:CLVS) announced today updated findings from its
ongoing Phase 2 clinical study of rociletinib (CO-1686), the Company’s
novel, oral, targeted covalent (irreversible) mutant-selective inhibitor
of the epidermal growth factor receptor (EGFR) for the treatment of
NSCLC in patients with initial activating EGFR mutations as well as the
primary resistance mutation T790M.
for Interim Data from Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling and Durable Clinical Activity and Progression-free Survival (PFS) in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC) investment picks